Paul Laviolette Buys 15,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) CEO Paul Laviolette purchased 15,000 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the transaction, the chief executive officer directly owned 15,000 shares of the company’s stock, valued at $295,350. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pulse Biosciences Price Performance

NASDAQ:PLSE opened at $23.30 on Wednesday. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $26.30. The company’s 50-day simple moving average is $20.93 and its 200 day simple moving average is $17.64. The firm has a market capitalization of $1.59 billion, a P/E ratio of -21.18 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.25 million. On average, equities research analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLSE. BNP Paribas Financial Markets lifted its position in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC increased its holdings in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the last quarter. KLP Kapitalforvaltning AS increased its holdings in Pulse Biosciences by 136.0% during the third quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after buying an additional 3,400 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Pulse Biosciences during the second quarter valued at approximately $158,000. Institutional investors own 76.95% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on PLSE. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 20th. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $30.00.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.